Targeting immune cells to improve treatment for bacterial sepsis
Targeting macrophage maladaptation for bacterial sepsis treatment
This study is looking at how certain immune cells, called macrophages, act during bacterial sepsis, a serious condition that can cause organ failure, to find new ways to help patients recover better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Acepre, LLC NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10868528 on NIH RePORTER |
What this research studies
This research investigates how immune cells called macrophages behave during bacterial sepsis, a severe condition that can lead to organ failure and death. It focuses on two critical phases of sepsis: the initial hyperinflammatory response and the subsequent immunosuppression. By understanding the role of macrophages in these phases, the research aims to develop new treatment strategies that could improve patient outcomes. The approach involves studying the cellular mechanisms and metabolic changes in macrophages to identify potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bacterial sepsis who are experiencing severe inflammatory responses.
Not a fit: Patients with non-bacterial infections or those who are not in the acute phase of sepsis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bacterial sepsis, potentially reducing mortality rates and improving recovery times.
How similar studies have performed: Previous research has shown promise in targeting immune responses in sepsis, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Columbia, United States
- Acepre, LLC — Columbia, United States (Active)
Researchers
- Principal investigator: Zhu, Xuewei — Acepre, LLC
- Study coordinator: Zhu, Xuewei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.